Terms: = Salivary gland cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
65 results:
1. salivary gland carcinoma: Towards a more personalised approach.
Rached L; Saleh K; Casiraghi O; Even C
Cancer Treat Rev; 2024 Mar; 124():102697. PubMed ID: 38401478
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent salivary gland Carcinoma: A Retrospective Observational Study.
Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
[TBL] [Abstract] [Full Text] [Related]
3. Near-infrared photoimmunotherapy for salivary duct carcinoma.
Makino T; Sato Y; Uraguchi K; Naoi Y; Fukuda Y; Ando M
Auris Nasus Larynx; 2024 Apr; 51(2):323-327. PubMed ID: 37775468
[TBL] [Abstract] [Full Text] [Related]
4. [Special tumor entities in the head and neck region: nasopharyngeal, salivary gland, and thyroid cancer].
Zech HB; Betz CS
HNO; 2023 Jul; 71(7):453-461. PubMed ID: 37294335
[TBL] [Abstract] [Full Text] [Related]
5. Adenoid cystic carcinoma of the salivary glands: a pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis.
Michaelides I; Künzel J; Ettl T; Beckhove P; Bohr C; Brochhausen C; Mamilos A
Eur Arch Otorhinolaryngol; 2023 Jun; 280(6):2937-2944. PubMed ID: 36856809
[TBL] [Abstract] [Full Text] [Related]
6. Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens.
Yamanaka S; Suzuki S; Ito H; Sivasundaram K; Hanamura I; Okubo I; Yoshikawa K; Ono S; Takahara T; Satou A; Tsuzuki T; Ueda R; Ogawa T; Fujimoto Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675234
[TBL] [Abstract] [Full Text] [Related]
7. Mucoepidermoid carcinoma (MEC) and adenosquamous carcinoma (ASC), the same or different entities?
White VA; Hyrcza MD; Lennerz JK; Thierauf J; Lokuhetty D; Cree IA; Indave BI
Mod Pathol; 2022 Oct; 35(10):1484-1493. PubMed ID: 35871081
[TBL] [Abstract] [Full Text] [Related]
8. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
9. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage salivary gland cancer.
Nakano T; Yasumatsu R; Hashimoto K; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
In Vivo; 2022; 36(2):979-984. PubMed ID: 35241559
[TBL] [Abstract] [Full Text] [Related]
10. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract] [Full Text] [Related]
11. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.
Benvenuto M; Ciuffa S; Focaccetti C; Sbardella D; Fazi S; Scimeca M; Tundo GR; Barillari G; Segni M; Bonanno E; Manzari V; Modesti A; Masuelli L; Coletta M; Bei R
Sci Rep; 2021 Sep; 11(1):19051. PubMed ID: 34561494
[TBL] [Abstract] [Full Text] [Related]
12. Updates in the molecular pathology of non-small cell lung cancer.
Paver E; O'Toole S; Cheng XM; Mahar A; Cooper WA
Semin Diagn Pathol; 2021 Sep; 38(5):54-61. PubMed ID: 33985831
[TBL] [Abstract] [Full Text] [Related]
13. The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma.
Chen Z; Ni W; Li JL; Lin S; Zhou X; Sun Y; Li JW; Leon ME; Hurtado MD; Zolotukhin S; Liu C; Lu J; Griffin JD; Kaye FJ; Wu L
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830080
[TBL] [Abstract] [Full Text] [Related]
14. Synergistic efficacy of combined egfr and HDAC inhibitors overcomes tolerance to egfr monotherapy in salivary mucoepidermoid carcinoma.
Parag-Sharma K; Tasoulas J; Musicant AM; do Nascimento-Filho CHV; Zhu Z; Twomey C; Liu P; Castilho RM; Amelio AL
Oral Oncol; 2021 Apr; 115():105166. PubMed ID: 33581505
[TBL] [Abstract] [Full Text] [Related]
15. The tumor immune contexture of salivary duct carcinoma.
Schvartsman G; Bell D; Rubin ML; Tetzlaff M; Hanna E; Lee JJ; Weber R; Phan J; Glisson BS; Ferrarotto R
Head Neck; 2021 Apr; 43(4):1213-1219. PubMed ID: 33576119
[TBL] [Abstract] [Full Text] [Related]
16. Targeting Notch and egfr signaling in human mucoepidermoid carcinoma.
Ni W; Chen Z; Zhou X; Yang R; Yu M; Lu J; Kaye FJ; Wu L
Signal Transduct Target Ther; 2021 Jan; 6(1):27. PubMed ID: 33473104
[TBL] [Abstract] [Full Text] [Related]
17. A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring egfr exon 19 deletion.
Xie X; Lin X; Liu M; Qin Y; Ouyang M; Li S; Gu Y; Chen S; Xiang J; Zhou C
Diagn Pathol; 2020 Jun; 15(1):71. PubMed ID: 32505185
[TBL] [Abstract] [Full Text] [Related]
18. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract] [Full Text] [Related]
19. Concurrent Identification of Novel egfr-SEPT14 Fusion and ETV6-RET Fusion in Secretory Carcinoma of the salivary gland.
Black M; Liu CZ; Onozato M; Iafrate AJ; Darvishian F; Jour G; Cotzia P
Head Neck Pathol; 2020 Sep; 14(3):817-821. PubMed ID: 31502214
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic markers in salivary gland cancer and their impact on survival.
Szewczyk M; Marszałek A; Sygut J; Golusiński P; Golusiński W
Head Neck; 2019 Sep; 41(9):3338-3347. PubMed ID: 31246357
[TBL] [Abstract] [Full Text] [Related]
[Next]
